Praxis Precision Medicines, Inc. (PRAX) Dividend History

Praxis Precision Medicines, Inc. (PRAX) is a biotechnology company focused on developing targeted therapies for neuroscience and rare diseases. The company leverages precision medicine approaches to create treatments tailored to specific genetic and molecular profiles, aiming to improve outcomes for patients with neurological and neuropsychiatric conditions.

99 High Street, 30th Floor, Boston, MA, 02110
Phone: 617-300-8460
Website: https://www.praxismedicines.com

Dividend History

Praxis Precision Medicines, Inc. currently does not pay dividends

Company News

  • Praxis Precision Medicines to Participate in Upcoming Fireside Chat

    Praxis Precision Medicines will participate in a virtual fireside chat on September 2, 2025, discussing their latest research and data from the 36th International Epilepsy Consortium, focusing on CNS disorders and genetic epilepsies.

    GlobeNewswire Inc.
  • Praxis (PRAX) Q2 Loss Widens 90%

    Praxis Precision Medicines reported a wider Q2 2025 loss of ($3.31) per share, with no revenue and doubled research expenses. The company continues advancing clinical trials for neurological disorder treatments, with promising results in epilepsy drug vormatrigine and receiving Breakthrough Therapy Designation for relutrigine.

    The Motley Fool
  • Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst

    Needham initiated coverage on Praxis Precision Medicines Inc (NASDAQ:PRAX), a clinical-stage biopharmaceutical company, engaged in the development of therapies for central nervous system disorders. The company’s lead product ulixacaltamide for essential tremor (ET) is undergoing Essential3 Phase 3 program, with topline results expected in the second half of 2024 to support a planned New Drug Application (NDA) submission in 2025. The analyst writes that sales of Ulixa for essential tremor (ET), if successful in Phase 3, could peak at over $1 billion in 2030 (60% probability of success). Needham writes, “value of ulixacaltamide in essential tremor alone is underappreciated at current levels.” The analyst initiates with a Buy rating and a price target of $145. The company’s second ...Full story available on Benzinga.com

    Benzinga
  • JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals

    JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.

    Zacks Investment Research
    Featured Companies: ALXO ANVS JAZZ
  • PPI Report Live: Producer Price Inflation Report Is Out, Here’s What It Shows

    What the latest PPI inflation data signals for inflation & the stock market today. The post PPI Report Live: Producer Price Inflation Report Is Out, Here’s What It Shows appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
    Featured Companies: DIA QQQ SBFM SHFS SPY
Page data last updated 09/07/2025 04:17:51 UTC